As executive vice president of USF Health, Dr. Lockwood leads the Morsani College of Medicine (MCOM), the Taneja College of Pharmacy, and the Colleges of Nursing and Public Health, Schools of Physical Therapy & Rehabilitation Sciences and Graduate Biomedical Sciences and the Athletic Training and Physician Assistant programs. He also oversees the USF Health faculty group practice, which with more than 1,000 providers is one of the largest multi-specialty practices in Florida. Dr. Lockwood also serves as the MCOM dean and as a professor in its Department of Obstetrics & Gynecology. He holds a secondary appointment as a professor in the USF College of Public Health. Dr. Lockwood assumed all these leadership roles when he joined USF Health in May 2014 and has served as executive vice president and chief academic officer at Tampa General Hospital (TGH) since 2015.

As dean of the Morsani College of Medicine, Dr. Lockwood has overseen a major re-organization of all three missions – education, research, and clinical care. Applications to the school have increased 30% over the past 10 years, while the median MCAT score has increased from the 78th to 97th percentile and the mean GPA of matriculants has increased from 3.5 to 3.95. Student performance on the USMLE Step 1 and 2 exams has dramatically improved and over 98% of students complete research theses. The percentage of students recruited from groups traditionally underrepresented in medicine (URM) has also increased from 7% in 2014 to 18% in 2024.

Beginning in 2015, Dr. Lockwood focused recruitment of investigators funded by the National Institutes of Health (NIH) on newly created cardiovascular and neuroscience institutes and a global infectious disease program. Because of aggressive recruitment, total MCOM faculty research awards, including that of faculty based at USF Health affiliates, increased from $128 million in 2014 to $345 million in 2024 and NIH grant expenditures increased from $72 million to around $179 million. In addition, non-cancer clinical trial funding has tripled to over $20 million. Dr. Lockwood helped establish several novel cross-campus transdisciplinary programs, such as a Medical Engineering Department. Driven by these successes, MCOM’s U.S. News & World Report (USNWR) research and primary care rankings have climbed from 80^th and 96^th in 2014 to 50^th and 46^th in 2023, respectively, making MCOM the fastest-rising research medical school in these rankings for the past decade. MCOM now has seven academic departments that rank among the top 50 in the nation for NIH-funded research. Driven in large part by this increase in research funding, USF was recently invited to join the Association of American Universities (AAU).

In the clinical practice, from fiscal year 2014 to fiscal year 2022, patient volume grew 40%, revenue increased more than 100%, from $192 million to $405 million. Perfect quality scores were achieved in the Medicare Merit-Based Incentive Payment System (MIPS) in two of the past three years and substantial improvements occurred in the practice’s Press-Ganey patient satisfaction scores. In 2020, USF Health completed an enhanced affiliation agreement with its primary teaching hospital, Tampa General, that includes integration of clinical services to form a robust, financially sound academic health center. The core of the integration is a 1,600-person management service organization, jointly owned by the university and hospital, termed USF Tampa General Physicians. This integration “de-risks” the university, provides much needed capital for expansion, and increases academic support. In 2024, USF and TGH revised and expanded this agreement to provide a historic new alignment between the two organizations that will allow USF Health to expand across all three mission areas. Multiple TGH clinical service lines have been formed led by USF faculty and the number of top-ranked USNWR specialties at TGH has increased from 3 to 8 in 10 years. 

Internationally known for his research expertise in obstetrics and gynecology, Dr. Lockwood is credited with leading a research team that discovered fetal fibronectin (fFN), the first biochemical predictor of prematurity. His lab also uncovered the seminal role of tissue factor in regulating endometrial hemostasis and menstruation, identified the hemostatic and vascular mechanisms for contraceptive-associated abnormal uterine bleeding and discovered a link between down-regulation of progesterone receptor activity and various causes of preterm birth. Dr. Lockwood maintains an active laboratory at USF Health dedicated to research in these areas. He and his team have been awarded five patents and are the recipients of long-standing grant support from the NIH, the March of Dimes and other foundations.

He has chaired and/or served on multiple committees of the American College of Obstetricians and Gynecologists (ACOG), NIH, and the Food and Drug Administration. He served on the national board of the March of Dimes Foundation and is past president of the American Gynecological and Obstetrical Society and the Society for Reproductive Investigation (SRI), the largest international reproductive science organization. Dr. Lockwood has been a tireless advocate for the training of physician-scientists.  He currently serves as a professional member of the Liaison Committee on Medical Education (LCME), which accredits U.S. allopathic medical schools.

Dr. Lockwood is a prolific writer, having authored more than 322 peer-reviewed publications (Google H-index of 94; i10-index of 354; 33,722 citations as of 9/24/24), 290 editorials, textbook chapters, and reviews, authored or co-authored three books and co-edited seven major textbooks, three with multiple editions. He is the lead editor of the 9th Edition of Creasy & Resnik’s Maternal Fetal Medicine, the leading textbook in the field. He is obstetrics section editor for UpToDate and was the long-standing editor-in-chief of Contemporary OB/GYN, where his editorials won six national publication awards.

He has been elected to the National Academy of Medicine (formerly the Institute of Medicine) and the American Association for the Advancement of Science (AAAS). He is a recipient of the SRI President’s Distinguished Scientist Award, the Society for Maternal-Fetal Medicine’s Lifetime Achievement Award, the National Institute of Child Health and Human Development Frontiers in Reproduction Beacon Award for research mentorship and the International Academy of Cardiovascular Sciences Lifetime Achievement Award. He is an honorary fellow of the Royal College of Obstetricians and Gynaecologists and a recipient of the University of Maryland Dean’s Distinguished Gold Medal. In addition, Dr. Lockwood is a recipient of the ACOG Public Service Award for his “enduring commitment to women’s health,” and a leadership award named in honor of Clotilde Dent Bowen from The Ohio State University College of Medicine.

Dr. Lockwood graduated magna cum laude from Brown University with special distinction in his major of developmental biology, received his medical degree from the University of Pennsylvania and a Master of Science in Healthcare Management from the Harvard School of Public Health. He served his residency in obstetrics and gynecology at Pennsylvania Hospital and his fellowship in maternal-fetal medicine at Yale-New Haven Hospital. He has been elected to the Phi Beta Kappa, Sigma Xi, and Alpha Omega Alpha honor societies.  

Before joining USF Health, Dr. Lockwood was vice president and dean at The Ohio State University College of Medicine. Prior to joining Ohio State, he spent nine years as the Anita O'Keeffe Young Professor of Women's Health and chair of the Department of Obstetrics, Gynecology and Reproductive Sciences at the Yale School of Medicine, where he also chaired the Yale Medical Group Board of Governors. Prior to his post at Yale, he served as the Stanley H. Kaplan Professor and chair of the Department of Obstetrics and Gynecology at the New York University School of Medicine, where he also served as interim director of its NCI-designated Kaplan Cancer Center. 

He is a dedicated teacher and a recipient of the Gerold L. Schiebler Advocate for Medical Students Award from the Florida Medical Association. Dr. Lockwood's clinical interests include the prevention of recurrent pregnancy loss, preterm delivery, and maternal thrombosis. He has been cited on the Best Doctors in America and other such national and local lists for over two decades. 

He is committed to Florida’s public health, serving as president of the Florida Medical School Quality Network, which oversees quality improvement projects for Florida’s Medicaid program. He also serves on the Board of Governors of the Florida Medical Association, and on the Hillsborough County Medical Association’s Executive Committee. He received the Hillsborough County Medical Association’s Frederick A. Reddy Memorial Award for dedication to “the art of medicine, community service, and social justice,” and the South Tampa Chamber of Commerce Citizen of the Year for his leadership during the COVID-19 pandemic. 

Dr. Lockwood is deeply committed to Tampa Bay’s economic success, serving on the boards of the Tampa Downtown Partnership, the Tampa Bay Economic Development Council and the Tampa Bay Chamber of Commerce. He has been named to the Tampa Bay Business Journal’s Top 25 People to Watch twice, and to its Power 100 Most Influential Leaders four times.